Literature DB >> 11396047

Clinical manifestations and incidence of oculo-respiratory syndrome following influenza vaccination--Quebec, 2000.

N Boulianne1, G De Serres, B Duval, R Shadmani, L Rochette.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11396047

Source DB:  PubMed          Journal:  Can Commun Dis Rep        ISSN: 1188-4169


× No keyword cloud information.
  5 in total

1.  Technical guidelines for the application of seasonal influenza vaccine in China (2014-2015).

Authors:  Luzhao Feng; Peng Yang; Tao Zhang; Juan Yang; Chuanxi Fu; Ying Qin; Yi Zhang; Chunna Ma; Zhaoqiu Liu; Quanyi Wang; Genming Zhao; Hongjie Yu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Low risk of recurrence of oculorespiratory syndrome following influenza revaccination.

Authors:  Danuta M Skowronski; Barbara Strauss; Perry Kendall; Bernard Duval; Gaston De Serres
Journal:  CMAJ       Date:  2002-10-15       Impact factor: 8.262

3.  Short and long-term safety of the 2009 AS03-adjuvanted pandemic vaccine.

Authors:  Gaston De Serres; Marie-Claude Gariépy; Brenda Coleman; Isabelle Rouleau; Shelly McNeil; Mélanie Benoît; Allison McGeer; Ardith Ambrose; Judy Needham; Chantal Bergeron; Cynthia Grenier; Kenna Sleigh; Arlene Kallos; Manale Ouakki; Najwa Ouhoummane; Grant Stiver; Louis Valiquette; Anne McCarthy; Julie Bettinger
Journal:  PLoS One       Date:  2012-07-03       Impact factor: 3.240

4.  Safety and immunogenicity of 2010–2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: results of a randomized trial.

Authors:  David W Scheifele; Marc Dionne; Brian J Ward; Curtis Cooper; Otto G Vanderkooi; Yan Li; Scott A Halperin
Journal:  Hum Vaccin Immunother       Date:  2013-01       Impact factor: 3.452

Review 5.  Influenza.

Authors:  Karl G Nicholson; John M Wood; Maria Zambon
Journal:  Lancet       Date:  2003-11-22       Impact factor: 79.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.